Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the US FDA for its bispecific antibody (BsAb), ZGGS15, which targets LAG-3 and TIGIT in advanced solid tumors. This marks ZGGS15 as the world’s first BsAb of its kind to reach the clinical stages.
ZGGS15’s Mechanism of Action and Preclinical Performance
ZGGS15 is designed to activate the TCR signaling pathway by effectively blocking the signaling pathway of LAG-3 and its ligand MHC-II, as well as blocking the signaling pathway of TIGIT and its ligand PVR. Additionally, ZGGS15 promotes PVR to combine with CD226, producing costimulatory activation signals that enhance the activation and proliferation of T cells and NK cells, leading to cytokine production. This mechanism positions ZGGS15 as a molecule capable of synergistically enhancing the immune system’s ability to eliminate tumor cells.
In preclinical animal models, ZGGS15 demonstrated an excellent anti-tumor proliferation effect when used alone. Furthermore, the combination of ZGGS15 and an anti-PD-1 antibody showed a superior synergistic effect on anti-tumor proliferation compared to the combination of anti-LAG-3 monoclonal antibody (mAb) or anti-TIGIT mAb/anti-PD-1 antibody. These results suggest that ZGGS15 may have a significant anti-tumor treatment effect in upcoming clinical trials.-Fineline Info & Tech
